Abstract-The performance of transabdominal ultrasound (US) in chronic pancreatitis (CP) following the advances in US technology made during recent decades has not been explored. Our aim in this prospective study was to evaluate the diagnostic accuracy of modern abdominal US compared with the Mayo score in CP. One hundred thirty-four patients referred for suspected CP were included in the study. Fifty-four patients were assigned the diagnosis CP. After inclusion, transabdominal US was performed. Ductal features (calculi, dilations and caliber variations, sidebranch dilations and hyper-echoic duct wall margins) and parenchymal features (calcifications, cysts, hyperechoic foci, stranding, lobulation and honeycombing) were recorded. Features were counted and scored according to a weighting system defined at the international consensus meeting in Rosemont, Illinois (Rosemont score). Diagnostic performance indices (95% confidence interval) of US were calculated: The unweighted count of features had a sensitivity of 0.69 (0.54-0.80) and specificity of 0.97 (0.90-1). The Rosemont score had a sensitivity of 0.81 (0.69-0.91) and specificity of 0.97 (0.90-1). Exocrine pancreatic failure was most pronounced in Rosemont groups I and II (p , 0.001). We conclude that using both unweighted and weighted scores, the diagnostic accuracy of modern transabdominal US is good. The extent of pancreatic changes detected by the method is correlated with exocrine
INTRODUCTION
Modern guidelines and reviews on chronic pancreatitis (CP) include transabdominal ultrasound (US) as a relevant first-line imaging method in the evaluation of the pancreas (Conwell et al. 2014; Drewes et al. 2015; Erchinger et al. 2011; Forsmark 2013; Martinez et al. 2013; Mayerle et al. 2013) . No prospective studies have reported the diagnostic performance using the most recent US technology. Endoscopic US (EUS) with characterization of ductal and parenchymal changes with or without the aid of weighted scores like the ''Rosemont score'' (Catalano et al. 2009 ) is presently the gold standard for sonographic imaging of the pancreas in CP. The Rosemont score was established through an international consensus meeting in Rosemont, Illinois (April 13-14, 2007) . The result of the conference was agreement on definitions and weighting for five parenchymal and five ductal features of CP. The diagnostic quality of EUS compared with other imaging modalities like computed tomography (CT) and magnetic resonance imaging (MRI) is regarded as good (Catalano et al. 1998; Kalmin et al. 2011; Luetmer et al. 1989; Manfredi et al. 2000; Pungpapong et al. 2007; Wiersema and Wiersema, 1995) . The severity of pathologic EUS changes correlates to histopathologic Ultrasound in Med. & Biol., Vol. 43, No. 4, pp. 735-743, 2017 Ó 2016 The Authors. Published by Elsevier Inc. on behalf of World Federation for Ultrasound in Medicine & Biology Printed in the USA.
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http://dx.doi.org/10. 1016/j.ultrasmedbio.2016.11.020 findings and extent of exocrine dysfunction (Albashir et al. 2010; Catalano et al. 1998; Chong et al. 2007; Kalmin et al. 2011; Luetmer et al. 1989; Manfredi et al. 2000; Pungpapong et al. 2007; Wiersema and Wiersema, 1995) . However, low inter-rater agreement, especially for the minor EUS-detected features in the Rosemont score, has been reported (Del et al. 2012; Kalmin et al. 2011; Stevens et al. 2010) . The invasive character of the EUS examination and the long learning curve for operators are drawbacks of the method. Transabdominal US is limited by longer sound wave distance to the pancreas compared with EUS. Bowel gas, obesity and individual patient factors reduce the quality of US images. Previous studies have explored the visualization of morphologic changes in CP by transabdominal US and reported varying diagnostic accuracy with a sensitivity of 70% to 80% (Bolondi et al. 1989; Foley et al. 1980; Gebel et al. 1985; Ikeda et al. 1994; Martinez-Noguera and D'Onofrio 2007) . One large study reported sensitivities for US .85% for the features calcifications, pancreatic duct dilations and cysts, compared with CT (Ikeda et al. 1994 ). In recent decades, there has been an overall advance in US technology Whitsett 2009 ). Re-evaluation using modern technology is warranted (Conwell et al. 2014) . The advances in software and screen technology and the introduction of harmonic imaging reduce noise and improve image resolution in all US systems. Modern US probes with dynamic frequencies, better depth-focusing technology and better high-frequency probes also add significantly to noise reduction and improved resolution. Especially in the characterization of calcifications, where the evaluation of shadowing is highly significant, overall reduction of random noise features is important. In the detection of minor changes in pancreatic ducts and parenchyma, we postulate that improved image resolution probably increases the sensitivity of the method compared with earlier studies.
In this prospective observational cohort study, our aim was to evaluate the diagnostic accuracy of features detected by a high-end transabdominal US scanner compared with the CP diagnosis defined by a diagnostic score combining clinical and imaging features, the Mayo score (Layer et al. 1994) . Furthermore, US findings were evaluated according to criteria from the Rosemont consensus to address possible improvements in diagnostic accuracy from a weighted score.
METHODS

Participants
One hundred forty-one eligible participants were recruited among patients referred to our outpatient clinic with suspected CP. Reasons for referral were presenting symptoms or classic CP characteristics based on previous diagnostic imaging. Patients who did not fulfill the protocol for an adequate Mayo score were not included. We excluded patients for whom US visualization of the pancreas was insufficient because of obesity, repeated overlying bowel air or other factors. The final number of patients was 124. Patient characteristics are summarized in Table 1 .
Diagnostic standards
Relevant clinical data and imaging reports from EUS (n 5 74), pancreatic CT (n 5 111) and/or pancreatic MRI (n 5 22) were retrieved from the medical records or obtained as necessary for the clinical workup. All EUS examinations were performed according to a modern standard using the linear EG-3870 UTK or radial EG-3670 URK scope from Pentax Medical (Pentax Europe, Hamburg, Germany) by two experienced operators whose focus is pancreatic EUS. CT and MRI scans were performed according to standardized and similar protocols at different hospital scanners as part of the routine diagnostic workup. All CT protocols included intravenous contrast.
Mayo score
On the basis of clinical information, endocrine and exocrine failure, and findings on CT, MRI and EUS, patients were diagnosed according to a modified Mayo score (also named Layer score) Layer et al. 1994) (Table 2 ). Patients with a Mayo score $4 were diagnosed with CP.
Sonographic examination
After overnight fasting, patients were examined with US while in the supine or right lateral position, with the Complete US scanning of the pancreas was performed. The ductal and parenchymal features ( Fig. 1 ) were recorded on a standardized form. The visibility of pancreatic head, body and tail was graded from 1 to 4 (1 5 good, 2 5 adequate, 3 5 poor, 4 5 not visible). The data were acquired from the segments of the pancreas with the best visualization.
Rosemont score
The weighted Rosemont score for EUS-detected features of CP comprises five parenchymal and five ductal features (Catalano et al. 2009 ). These features with definitions and weighting are described in Table 3 . We applied the definitions and weighting unchanged from the Rosemont consensus on the detected transabdominal US features. 
Classic scoring of sonographically detected features
The classic EUS assessment of sonographic features in CP is performed by counting the features detected in each patient. Traditionally, a cutoff of three to five features has been considered for the diagnosis of CP (Catalano et al. 1998; Iglesias-Garcia et al. 2015; Sahai et al. 1998; Stevens et al. 2010; Wiersema et al. 1993) . We also performed an unweighted counting of the USdetected features. In our study, we chose to use three features as the cutoff for calculation of accuracy. Others have described the registration of nine EUS features ). For simplicity, we chose to use all 10 Rosemont EUS features as the basis for the counting.
Exocrine function testing
Pancreatic exocrine function was evaluated using a timed, secretin-stimulated endoscopic short test described elsewhere Tjora et al. 2013 ). Patients were offered conscious sedation with intravenous midazolam during the test procedure. The peak bicarbonate concentration was measured; the cutoff for exocrine failure was defined as ,80 mmol/L (Conwell et al. 2003; Erchinger et al. 2013; Stevens et al. 2008) .
Fecal elastase 1 was analyzed with a commercial monoclonal analysis kit (ScheBo Biotech, Giessen, Germany). A fecal elastase 1 level ,200 mg/mg was considered pathologic (Loser et al. 1996) . Patients with both tests under threshold were considered exocrine insufficient according to the Mayo score.
Statistical analysis
Statistics were calculated using SPSS Version 22 (IBM, Armonk, NY, USA) and SigmaPlot 11 (Systat Software, San Jose, CA, USA). Normal distribution of the samples was tested with the Kolmogorov-Smirnov 
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RESULTS
Participants
Patient enrollment was conducted during the period January 2011 to June 2016. One hundred forty-one eligible patients were evaluated. Seven patients did not fulfill the protocol for an adequate Mayo score and were not included. Ten patients (7%) who had insufficient US visualization of the pancreas were excluded. A few patients were included despite missing values for one of the exocrine tests or missing demographics. Accordingly, we included 124 patients with acceptable-quality US. Patient inclusion and exclusion are displayed in Figure 2 . CP was diagnosed in 54 patients with a Mayo score $4. Seventy patients with varying diagnoses (recurrent acute pancreatitis, functional dyspepsia, bile stone disease or other cause of abdominal pain) were assigned a Mayo score ,4. These patients were included as a control group. The Rosemont score from US categorized the patients into four groups: (I) consistent with CP (n 5 31), (II) suggestive of CP (n 5 14), (III) indeterminate for CP (n 5 10) and (IV) normal pancreas (n 5 69). The CP patients had lower body mass indexes and higher median HbA1c values; a larger percentage of CP patients was smokers and had reduced exocrine pancreatic function compared with the non-CP group. Median alcohol intake at the time of inclusion was lower in the CP than in the non-CP group. There were no differences between the groups with respect to age or sex. Other than some discomfort accompanying the endoscopic examinations, no adverse events were reported during any of the examination procedures.
Visualization
Of the 134 total eligible patients who fulfilled the Mayo score, the whole pancreas could be visualized in 82 patients (61%) (visualization score #2 in all 3 segments), and sufficient visualization for inclusion was achieved in 124 patients (92%). The pancreatic tail was the part of the pancreas most frequently incompletely visualized (34 patients, 25%). In 10 patients, visualization of the entire pancreas was inadequate to determine a US score.
Visualization of calcifications and cysts by US
We calculated inter-rater agreement between US and CT for calcifications and cysts. The calculation was performed on the subgroup of 111 patients for whom CT scans were available. US and CT detection of calcifications were in almost perfect agreement (k 5 0.91). Agreement between US detection and CT detection of cysts was substantial (g 5 0.69).
Diagnostic accuracy of transabdominal US
We calculated ROC curves for the two US scoring methods (Rosemont and classic scores) against the diagnosis CP by Mayo score (Fig. 3) . Cutoffs for the sonographic diagnosis were defined as a classic score of $3 and Rosemont categories I and II. Both scoring systems yielded very high accuracies of $0.95 (Table 4) . There was somewhat better sensitivity and specificity for US in the Rosemont score compared with the classic score for the suggested cutoffs, but the difference between the areas under the ROC curves did not reach statistical significance (Fig. 3) . We performed a subanalysis on the group with minimal change CP represented by Mayo scores 0-6 (n 5 90). In this group we calculated a sensitivity of 0.55 (0.32-0.77) and a specificity of 0.99 (0.92-1) for the Rosemont score.
Rosemont US category and exocrine function
When we divided the patients into groups with prominent US changes (US Rosemont categories I and II) and less prominent US changes (US Rosemont categories III and IV), we found that the groups with the most prominent changes also had the most severe exocrine failure (p , 0.001) and the highest prevalence of exocrine failure (p , 0.001) (Fig. 4) .
DISCUSSION
To our knowledge, this is the only prospective clinical report evaluating the use of transabdominal US compared with a relevant diagnostic standard for CP during the last 20 y. We applied two different scoring systems developed for EUS to the pancreatic US findings in a population of well-characterized patients. Our study had three main findings: First, we found that pancreatic US has good diagnostic accuracy for diagnosing CP in both scoring systems. We also found that disease severity represented by grade of exocrine failure was correlated to severity of sonographic changes in the CP group. The agreement between transabdominal US and CT in the detection of calcifications and cysts was excellent.
Knowledge of the diagnostic performance of transabdominal US in CP is based on old studies (Bolondi et al. 1989; Foley et al. 1980; Gebel et al. 1985; Ikeda et al. 1994) . The German clinical practice guideline for CP (Mayerle et al. 2013 ) describes the specificity of US as good (70%-97%), whereas the method has pitfalls with respect to sensitivity (60%-81%). Reports evaluating transabdominal US of the pancreas in CP after the substantial improvement in US and imaging technology during the last two decades have been requested (Conwell et al. 2014) . Our results confirm that dedicated transabdominal US of the pancreas has good specificity under adequate scanning conditions and that the overall accuracy has improved compared with most of the existing studies. The advantage of the Rosemont score over the traditional counting of EUS features has not been determined in EUS (Del et al. 2012; Kalmin et al. 2011; Stevens et al. 2010 ). We found that by applying the principles from the Rosemont consensus to transabdominal US findings we achieved better sensitivity for our suggested cutoffs, but the accuracy did not significantly differ. The most reliable and major features in the Rosemont score detected by US are calcifications. This feature is scored with the highest weight in the Rosemont score, whereas some minor features have poorer detection rate with US and are consequently weighted lower.
This study adds to our knowledge on the overall diagnostic accuracy of US features in CP, with use of a modern US scanner, and explores the advantage of weighted scores in the evaluation of findings obtained with this modality.
Methodologic considerations
The Rosemont score was developed to fit the performance of EUS. The score is not validated for US. Direct Table 4 . 
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Ultrasound in Medicine and Biology Volume 43, Number 4, 2017 adaption to transabdominal US with lower scan frequencies and much longer sound wave distance to examined structures may be difficult. The limitations in inter-rater agreement for defined sonographic features of CP described earlier for EUS may also be a limitation for transabdominal US. The operators discussed and agreed on general definitions of the individual features before starting the study. We did not analyze inter-rater agreement.
The detail in EUS is superior to that in most US examinations. The depth and probe frequency may interfere with the interpretation of US features. However, under perfect sonographic conditions in non-obese individuals and with the additional use of transabdominal highfrequency probes, we were able to obtain high-quality images of the whole or a sufficient part of the pancreas. In many cases we failed to obtain a complete US image of the pancreas from body to tail. This may reduce sensitivity in cases of focal disease. For some features, the frequency of the transducer may play a role. Interface echoes appear as the US traverses echo-rich structures and layers. Ductal walls reflect a more prominent echo at lower US frequency than at higher US frequency. This may have implications for the interpretation of ductal structures. Because of interface echo differences, the cutoff values of EUS for main ductal dilation may be inappropriate for US measures. However, in the present study, we did not alter this definition. We strictly applied the ''leading edge to leading edge'' measurement principle (Erchinger et al. 2011) to minimize the effect of transducer frequency variation.
For visualization of calcifications and cysts with unspecified location, we found that US performed well compared with CT. On the other hand, differentiation between intra-and extra-ductal locations of the calcifications and the detection of minor features such as stranding, minor duct dilations and duct wall hyperechogenicity are challenging in US. We postulate that because of the higher spatial resolution of EUS, the detection of these weaker features is more relevant for the EUS modality. This may explain why the weighted score, in which major features are given a high weighting, performs better on US.
Diagnostic standards for CP are challenging, and a new definition has been proposed (Whitcomb et al. 2016) . The old Cambridge criteria (Sarner and Cotton, 1984) are based on endoscopic retrograde cholangiopancreatography (ERCP) and, thus, not practically applicable as a modern standard because ERCP is no longer a frequently used diagnostic modality. The most widespread standard is the M-ANNHEIM criteria (Schneider et al. 2007 ). This comprehensive classification system comprises several subsystems for diagnostic definition, risk factor classification, disease staging and multimodal image evaluation. For research, the system has drawbacks in its complexity.
We chose to use the simple diagnostic MAYO score, originally developed by Peter Layer (Layer et al. 1994 ). This score combines imaging, histology, symptoms and features of exocrine and endocrine failure in a simple numerical score. The score was originally developed for calcifying alcoholic pancreatitis, and is not validated in all groups of CP. For both research and clinical purposes, this score has the advantage of a clear numerical diagnostic definition. The score probably has limitations in defining minimal-change CP.
Supplementary methods such as contrast-enhanced ultrasonography and elastography have been developed during the last decade. Small studies (Azemoto et al. 2015; Llamoza-Torres et al. 2016; Uchida et al. 2009; Yashima et al. 2012 ) have evaluated the performance of these modalities applied by external US in patients with CP, but at present no clinical consensus regarding CP has been arrived at with respect to these methods. The evaluation of such modalities was outside the scope of this study.
Study limitations
Studies on US and EUS are operator dependent. The examinations were performed by operators blinded to earlier history and radiologic imaging. Blinding to patient appearance and communication during the procedure was not feasible. Blinding biases may exist. Patients with poor sonographic imaging of the pancreas were excluded. Exclusions caused by obesity or bowel gas may introduce a selection bias.
In characterization of the patients, different image modalities (CT, MRI, EUS) were chosen as the best clinical approach in the diagnostic workup process. The use of different modalities may introduce variations in classifications. We argue that this reflects a realistic image of practical CP diagnostics.
The direct application of unadjusted EUS scoring systems may not be completely feasible for the USdetected features. To our knowledge, there are no validation studies on transcutaneous US using the Rosemont score.
CONCLUSIONS
We have reported a clinically relevant evaluation of the accuracy of transabdominal US of the pancreas using modern US technology. We found that the modality has good diagnostic accuracy and that the extent of sonographic changes is reflected by the grade of exocrine failure. Some minor features were difficult to visualize by the transabdominal approach. Adjustment of weighted scores to fit the performance of transabdominal US in practical CP diagnostics should be explored in future studies. Our results support the place of US as a simple, radiation-free and non-invasive first-line modality in the clinical workup of patients with CP.
